Features of Hormone Therapy after Surgeries for Thyroid Cancer

Main Article Content

N.V. Gulchiy
A.V. Dinets

Abstract

No abstract

Article Details

How to Cite
Gulchiy, N., and A. Dinets. “Features of Hormone Therapy After Surgeries for Thyroid Cancer”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 1.41, Feb. 2012, pp. 98-104, doi:10.22141/2224-0721.0.1.41.2012.176817.
Section
Literature Review

References

Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы. — М.: ГЭОТАР-Медиа, 2009. — С. 29-30.

Ларін О.С., Паньків В.І., Селіваненко М.І., Грачова О.О. Аналіз діяльності ендокринологічної служби України у 2010 році та перспективи розвитку медичної допомоги хворим з ендокринною патологією // Міжнародний ендокринологічний журнал. — 2011. — № 3(35). — С. 10-18.

Дедов И.И., Мельниченко Г.А., Трошина Е.А. и др. Спорные вопросы тактики лечения дифференцированного рака щитовидной железы // Пробл. эндокринол. — 2008. — Т. 54, № 2. — С. 14-22.

Национальные клинические рекомендации по диагностике и лечению дифференцированного рака щитовидной железы // Эндокринная хирургия. — 2008. — № 1(2). — С. 3-5.

Гарбузов П.И., Дроздовский Б.Я., Родичев А.А. и др. Радиойодтерапия рака щитовидной железы // Практическая онкология. — 2007. — Т. 8, № 1. — С. 42-45.

Pacini F., Schlumberger M., Dralle H. et al. The European thyroid cancer taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium // Eur. J. Endocrinol. — 2006. — Vol. 154. — P. 787-803.

Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973—2002 // JAMA. — 2006. — Vol. 295, № 18. — P. 2179-2182.

Jonklaas J., Sarlis N.J., Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy // Thyroid. — 2006. — Vol. 16. — P. 1229-1242.

Schlumberger M.J., Torlantano M. Papillary and follicular thyroid carcinoma // Baillieres Best Pract. Res. Clin. Endocrinol. Metab. — 2000. — Vol. 14, № 4. — P. 601-613.

Tuttle R.M., Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm // Endocrinol. Metab. Clin. North Am. — 2008. — Vol. 37. — P. 419-435.

Tuttle R.M., Ball D.W., Byrd D. et al. Thyroid carcinoma // J. Natl Compr. Canc. Netw. — 2010. — Vol. 8. — P. 1228-1274.

Hay I.D., Bergstralh E.J., Goellner J.R. et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 // Surgery. — 1993. — Vol. 114. — P. 1050-1057.

Byar D.P., Green S.B., Dor P. et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group // Eur. J. Cancer. — 1979. — Vol. 15. — P. 1033-1041.

Shaha A.R., Loree T.R., Shah J.P. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid // Surgery. — 1995. — Vol. 118. — P. 1131-1136.

Shaha A.R. Controversis in the management of thyroid nodule // Laryngoscope. — 2000. — Vol. 110. — P. 183-193.

Cooper D.S., SpeckerB., Ho M. et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry // Thyroid. — 1998. — Vol. 8. — P. 737-744.

Sawka A.M., Brierley J.D., Tsang R.W. et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer // Endocrinol. Metab. Clin. North Am. — 2008. — Vol. 37, № 2. — P. 457-480.

Hundahl S.A., Fleming I.D., Fremgen A.M. et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 // Cancer. — 1998. — Vol. 15, № 83(12). — P. 2638-2648.

Toft A.D. Clinical practice. Subclinical hyperthyroidism // N. Engl. J. Med. — 2001. — Vol. 345. — P. 512-516.

Kim S., Wei J.P., Braveman J.M., Brams D.M. Predicting outcome and directing therapy for papillary thyroid carcinoma // Arch. Surg. — 2004. — Vol. 139, № 4. — P. 393-394.

Lundgren C.I., Hall P., Dickman P.W., Zedenius J. Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer // Br. J. Surg. — 2007. — Vol. 94, № 5. — P. 571-577.

Hay I.D., Thompson G.B., Grant C.S. et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients // World J. Surg. — 2002. — Vol. 26, № 8. — P. 879-885.

DeGroot L.J., Kaplan E.L., McCormick M., Straus F.H. Natural history, treatment, and course of papillary thyroid carcinoma // J. Clin. Endocrinol. Metab. — 1990. — Vol. 71, № 2. — P. 414-424.

Mazzaferri E.L. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma // Thyroid. — 1997. — Vol. 7, № 2. — P. 265-271.

Sherman S.I., Brierley J.D., Sperling M. et al. Prospective multi-center study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group // Cancer. — 1998. — Vol. 83. — P. 1012-1021.

Brierley J.D., Panzarella T., Tsang R.W. et al. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example // Cancer. — 1997. — Vol. 79. — P. 2414-2423.

Loh K.C., Greenspan F.S., Gee L. et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients // J. Clin. Endocrinol. Metab. — 1997. — Vol. 82. — P. 3553-3562.

Wittekind C., Compton C.C., Greene F.L. et al. TNM residual tumor classification revisited // Cancer. — 2002. — Vol. 94. — P. 2511-2516.

Schlumberger M., Berg G., Cohen O. et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective // Eur. J. Endocrinol. — 2004. — Vol. 150. —

P. 105-112.

Rouxel A., Hejblum G., Bernier M.O. et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas // J. Clin. Endocrinol. Metab. — 2004. — Vol. 89. — P. 5362-5368.

Wenig B.M., Thompson L.D., Adair C.F. et al. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases // Cancer. — 1998. — Vol. 82. — P. 740-753.

Akslen L.A., Livolsi V.A. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma // Cancer. — 2000. — Vol. 88. — P. 1902-1908.

Demers L.M., Spencer C.A. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease // Clin. Endocrinol. (Oxf.). — 2003. — Vol. 58, № 2. — P. 138-140.

Whitley R.J., Ain K.B. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma // Clin. Lab. Med. — 2004. — Vol. 24. — P. 29-47.

Kloos R.T., Mazzaferri E.L. A single recombinant human thyrotropinstimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years la-ter // J. Clin. Endocrinol. Metab. — 2005. — Vol. 90. — P. 5047-

Links T.P., van Tol K.M., Jager P.L. et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis // Endocr. Relat. Cancer. — 2005. — Vol. 12, № 2. — P. 273-280.

Tuttle R.M., Leboeuf R. Follow-up approaches in thyroid cancer: a risk adapted paradigm // Endocrinol. Metab. Clin. North. Am. — 2008. — Vol. 37. — P. 419-435.

Маколина Н.П., Платонова Н.М. Современная парадигма послеоперационного ведения больных с дифференцированным раком щитовидной железы // Клиническая и экспериментальная тиреоидология. — 2011. — Т. 7, № 3. —

С. 8-21.

Mazzaferri E.L., Kloos R.T. Is Diagnostic Iodine-131 Scanning with Recombinant Human TSH Useful in the Follow-Up of Differentiated Thyroid Cancer after Thyroid Ablation? // J. Clin. Endocrinol. Metab. — 2002. — Vol. 87, № 4. — P. 1490-1498.

Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association managerment guidelines for patients with thyroid nodules and differentiated thyroid cancer // Thyroid. — 2009. — Vol. 19, № 11. — P. 1167-1214.

Wartofsky L. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after

recombinant human thyrotropin // Thyroid. — 2002. — Vol. 12. — P. 583-590.

Kloos R.T. Thyroid Cancer Recurrence in Patients Clinically Free of Disease with Undetectable or Very Low Serum Thyroglobulin Values // J. Clin. Endocrinol. Metab. — 2010. — Vol. 95, № 12. — P. 5241-5248.

Pacini F., Molinaro E., Castagna M.G. et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma // J. Clin. Endocrinol. Metab. — 2003. — Vol. 8. — P. 3668-3673.

Tuttle R.M. Risk-adapted management of thyroid cancer // Endocr. Pract. — 2008. — Vol. 14, № 6. — P. 764-774.